| Excerpt | Reference |
|---|
| "A cases of systemic lupus erythematosus is reported, presenting with urticaria-like lesions and complement deficiencies, which was completely controlled by dapsone." | ( Matthews, CN; Saihan, EM; Warin, RP, 1978) |
| "Patients with systemic lupus erythematosus are at increased risk for premature atherosclerosis." | ( Ginzler, E; Ilowite, NT; Jacobson, MS; Samuel, P, 1988) |
| "A case of cerebral systemic lupus erythematosus is presented." | ( Beacham, B; Klestov, A; Price, J; Roberts, C, 1985) |
| "Systemic lupus erythematosus is a polysystemic disease with a high incidence of associated glomerulonephritis." | ( , 1969) |
| "The pathogenesis of systemic lupus erythematosus is thought to be primarily under genetic control, with environmental factors playing a secondary role." | ( Kanwar, YS; Kumar, A; Reeves, WH; Satoh, M, 1995) |
| "Systemic lupus erythematosus is a challenging disease with varied manifestations resulting from widespread immune complex deposition." | ( Lehman, TJ, 1995) |
| "Systemic lupus erythematosus is characterized by the production of Abs to ribonucleoproteins, including Ro (or SS-A) and La (or SS-B)." | ( Harley, JB; Henry, WE; James, JA; Kurien, BT; Scofield, RH, 1996) |
| "Systemic Lupus Erythematosus is a disease commonly seen in women." | ( Biniyala, R; Borges, NE; Nadkar, MY; Samant, RS; Vaidya, S, 1995) |
| "Systemic lupus erythematosus is characterized by polyclonal B cell activation, the production of autoantibodies, and often by renal disease." | ( Butfiloski, EJ; DesJardin, LE; Schiffenbauer, J; Sobel, ES, 1996) |
| "Systemic lupus erythematosus is a multisystem inflammatory disease characterized by antinuclear antibody production." | ( Gilkeson, G; Pisetsky, DS; St Clair, EW, 1997) |
| "Bullous systemic lupus erythematosus is a generalized subepidermal blistering skin eruption in patients suffering from systemic lupus erythematosus." | ( Chan, LS; Chen, M; Lapiere, JC; Mancini, AJ; Marinkovich, MP; Paller, AS; Traczyk, T; Woodley, DT, 1999) |
| "Systemic lupus erythematosus is a non-organ specific, autoimmune disease characterised by antinuclear antibodies and vasculitis." | ( Austin, OM; Ramakrishnan, V; Raurell, A, 2000) |
| "Systemic lupus erythematosus is an autoimmune disorder that predominantly affects women during the childbearing years." | ( Kammer, GM; Tsokos, GC, 2000) |
| "Systemic lupus erythematosus is a chronic, multisystemic disease that mainly affects women of childbearing age." | ( Cuartero Lobera, J; Guillén Antón, J; Lirola Grajales, P; Martínez García, R; Pastor Tomás, E; Vaquerizo Gareta, A, 2001) |
| "Systemic lupus erythematosus is a disease of immune dysregulation that strikes approximately 1 in 2000 individuals." | ( Klein-Gitelman, M; Reiff, A; Silverman, ED, 2002) |
| "Systemic lupus erythematosus is a chronic autoimmune disease of unknown etiology with multisystem involvement." | ( Lindsley, CB; Samad, AS, 2003) |
| "Systemic lupus erythematosus is a multifactorial autoimmune disease of complex etiology, which may be associated with cognitive dysfunction, seizures, and headache." | ( Lam, AM; Rozet, I; Souter, M; Vavilala, MS, 2004) |
| "Bullous systemic lupus erythematosus is a rare disease associated with subepidermal blistering and, in most cases, severe systemic manifestations." | ( Bacman, D; Kuhn, A; Megahed, M; Ostendorf, B; Ruzicka, T; Schneider, M, 2004) |
| "Systemic lupus erythematosus is an autoimmune and inflammatory disease with multiple clinical manifestations, including arthropathy." | ( Fernández, A; Iglesias, A; Matteson, EL; Quintana, G; Restrepo, JF; Rondón, F; Sánchez, A, 2004) |
| "Systemic lupus erythematosus is an autoimmune disease primarily affecting women." | ( Jusko, WJ; Kamal, MA, 2004) |
| "Systemic lupus erythematosus is a systemic autoimmune disease characterized by inflammation in organs such as kidneys and presence of autoantibodies against nuclear antigens." | ( Joyce, S; Parekh, VV; Singh, AK; Singh, RR; Van Kaer, L; Wang, CR; Wei, J; Yang, JQ, 2005) |
| "Systemic lupus erythematosus is a disease of unknown cause that manifests with tissue and cellular alterations due to the deposition of antibodies and pathogenic immune complexes." | ( Brandolini, C; Compadretti, GC; Tasca, I, 2005) |
| "Systemic lupus erythematosus is an autoimmune disorder characterized by the production of pathogenic autoantibodies, primarily to nuclear antigens." | ( Diamond, B; Grimaldi, CM; Hill, L; Peeva, E; Xu, X, 2005) |
| "Patients with systemic lupus erythematosus are prone to various infections, often associated with high mortality." | ( Chiu, YL; Chu, TS; Hsueh, PR; Huang, JW; Wu, KD, 2005) |
| "Systemic lupus erythematosus is an autoimmune disease in which most patients express Abs that bind double-stranded DNA." | ( DeGiorgio, LA; Diamond, B; Huerta, PT; Kowal, C; Volpe, BT, 2006) |
| "Systemic lupus erythematosus is frequently accompanied by gastrointestinal symptoms, but colonic lesions are quite rare, and the regular treatment is not fixed yet." | ( Chino, Y; Goto, D; Hayashi, T; Ito, S; Matsumoto, I; Miyahara, S; Soeda, A; Sumida, T; Takahashi, R; Tsutsumi, A, 2005) |
| "Although systemic lupus erythematosus is the prototypical B-cell-mediated autoimmune disease, the role of lymphoid neogenesis in its pathogenesis is unknown." | ( Akaogi, J; Kelly, KM; Kuroda, Y; Lee, PY; Li, Y; Nacionales, DC; Reeves, WH; Satoh, M; Sobel, E; Weinstein, JS; Zhuang, H, 2006) |
| "Systemic lupus erythematosus is an autoimmune connective-tissue disorder with a wide range of clinical features, which predominantly affects women, especially from certain ethnic groups." | ( D'Cruz, DP; Hughes, GR; Khamashta, MA, 2007) |
| "Systemic lupus erythematosus is a chronic autoimmune condition with a wide spectrum of clinical manifestations, characterized by the production of auto-antibodies to components of the cell nucleus." | ( Moldovan, I, 2006) |
| "Systemic lupus erythematosus is an autoimmune disease caused by autoantibodies, including IgG anti-DNA." | ( Ebling, F; Hahn, BH; La Cava, A; Singh, RP; Wong, M, 2007) |
| "Systemic lupus erythematosus is a multisystem organ inflammation due to damage of cells and tissues by pathogenic auto-antibodies and immune complexes." | ( Das, S; Kar, C; Maiti, A; Pal, D; Roy, AK, 2007) |
| "Systemic lupus erythematosus is a multisystem autoimmune disorder." | ( Bahar, S; Dere, H; Karaaslan, Y; Ozcan, I; Ozcan, KM; Pasaoglu, L; Sennaroglu, E, 2007) |
| "Systemic lupus erythematosus is a frequent autoimmune disease, affecting several organs, including the brain, spinal cord and nerves." | ( Arányi, Z; Gaal, B; Ilniczky, S; Kamondi, A; Nagy, G; Szirmai, I; Várallyay, G, 2007) |
| "Systemic lupus erythematosus is an autoimmune and inflammatory disease characterized by a variety of symptoms, including arthropathy." | ( Cholongitas, E; Pipili, C; Sfritzeri, A, 2008) |
| "Systemic lupus erythematosus is associated with the production of antibodies to self-constituents, particularly those that target certain specific ribonucleoprotein (RNP) particles." | ( Bachmann, M; Kurien, BT, 2009) |
| "Systemic lupus erythematosus is a prototypical systemic autoimmune disease, affecting multiple organs and organ-systems, leading to a wide variety of symptoms, serological and clinical features." | ( Kiss, E; Szodoray, P, 2010) |
| "Systemic lupus erythematosus is a common autoimmune disease, with kidney involvement a serious complication associated with poor prognosis." | ( Akira, S; Hoi, A; Holdsworth, SR; Kitching, AR; O'Sullivan, KM; Odobasic, D; Ooi, JD; Steinmetz, OM; Summers, SA, 2010) |
| "Juvenile systemic lupus erythematosus is a rare multisystemic autoimmune disease with variable clinical manifestations, and disease onset before 16 years of age." | ( Gahr, M; Hahn, G; Hedrich, CM; Heubner, G; Laass, MW; Straub, S; Wieczorek, K; Zappel, H, 2011) |
| "Systemic lupus erythematosus is an autoimmune inflammatory disorder that frequently affects women of childbearing age." | ( Kodner, C; Michalski, JP, 2010) |
| "Systemic lupus erythematosus is a chronic inflammatory disorder that predisposes to acute coronary thrombosis." | ( Matthai, WH; Patel, PJ; Untereker, WJ, 2011) |
| "Systemic lupus erythematosus is a chronic-relapsing autoimmune disease of incompletely understood etiology." | ( Dozmorov, M; Jeffries, MA; Merrill, JT; Sawalha, AH; Tang, Y; Wren, JD, 2011) |
| "Systemic lupus erythematosus is an autoimmune disease with protean manifestation." | ( Singh, NK; Singh, S; Singh, U; Verma, PK, 2011) |
| "Systemic lupus erythematosus is a polymorphic and multigenic inflammatory autoimmune disease." | ( Bourguignon, JJ; Gazi, L; Keravis, T; Lugnier, C; Monneaux, F; Muller, S; Yougbaré, I, 2012) |
| "Systemic lupus erythematosus is an autoimmune disorder, which has a rare association with aplastic anaemia." | ( Ahmad, SQ; Khan, O; Zafar, SI; Zafar, SN, 2011) |
| "Systemic lupus erythematosus is a chronic autoimmune disorder which affects women with child bearing potential." | ( Kiss, E; Szegedi, G; Tarr, T; Zeher, M, 2012) |
| "Bullous systemic lupus erythematosus is extremely rare in children." | ( Poojary, S; Rais, S, 2012) |
| "Systemic lupus erythematosus is a systemic autoimmune disease characterized by the presence of myriad autoantibodies, some with pathogenic potential, and diverse clinical manifestations." | ( Putterman, C; Tagoe, C, 2012) |
| "Systemic lupus erythematosus is one of the autoimmune diseases characterized by multisystem involvement associated with autoantibody and immune complex vasculitis along with endothelial cell damage." | ( Basel, ME; Darweesh, HE; Safwat, M; Salama, MK; Taha, FM, 2012) |
| "Systemic lupus erythematosus is a chronic autoimmune disease characterized by an abundance of autoantibodies against nuclear antigens." | ( Bashmakov, A; Buggy, JJ; Chang, BY; Du, Y; Grewal, S; Hutcheson, J; Mohan, C; Sajitharan, D; Satterthwaite, AB; Vanarsa, K; Zhou, XJ, 2012) |
| "Systemic lupus erythematosus is one of the diseases, which can be associated with thrombotic microangiopathy." | ( Anguel, N; Bellon, N; Goujard, C; Lambotte, O; Vandendries, C, 2013) |
| "Systemic lupus erythematosus is a chronic inflammatory autoimmune disease characterized by autoantibodies specific for highly conserved nuclear antigens, such as double-stranded DNA, histones and ribonuclear proteins." | ( Colón, M; Hernán Martínez, J; Laboy Ortíz, IE; Moreno, M; Rodríguez, A; Sánchez, A; Vélez, FA, 2014) |
| "Systemic lupus erythematosus is an autoimmune disease characterized by the development of auto antibodies against a variety of self-antigens and deposition of immune complexes that lead to inflammation, fibrosis, and end-organ damage." | ( Carretero, OA; D'Ambrosio, M; Janic, B; Liao, TD; Nakagawa, P; Peterson, EL; Rhaleb, NE; Worou, ME; Yang, XP, 2015) |
| "Systemic lupus erythematosus is characterized by dysregulated activation of T and B cells and autoantibodies to nuclear antigens and, in some cases, lipid antigens." | ( Astudillo, H; Baeza, I; España, L; Estrada-García, I; Estrada-Parra, S; Flores-Romo, L; Landa, C; Reséndiz, A; Serafín-López, J; Tescucano, A; Wong, C; Wong-Baeza, C, 2015) |
| "Systemic lupus erythematosus is an autoimmune disease that affects many systems, including the skin, musculoskeletal, renal, neuropsychiatric, hematologic, cardiovascular, pulmonary, and reproductive systems." | ( Bieniek, ML; Ghetu, MV; Lam, NC, 2016) |
| "Systemic lupus erythematosus is an autoimmune disease that can affect numerous tissues and is characterized by the production of nuclear antigen-directed autoantibodies (e." | ( Al-Abed, Y; Altiti, A; Bloom, O; Cheng, KF; Coleman, TR; Crawford, JM; Diamond, B; Grant, C; He, M; Jeganathan, V; Kowal, C; Meurice, N; Papatheodorou, A; Sun, S; VanPatten, S; Volpe, BT, 2016) |
| "Conclusion Bullous systemic lupus erythematosus is an uncommon presentation of systemic lupus erythematosus." | ( Chanprapaph, K; Sawatwarakul, S; Vachiramon, V, 2017) |
| "Background Systemic lupus erythematosus is associated with an increased risk of cardiovascular disease." | ( Afeltra, A; Fasano, S; Margiotta, DP; Navarini, L; Pantano, I; Pierro, L; Riccardi, A; Valentini, G, 2017) |
| "Systemic lupus erythematosus is a multifactorial participant autoimmune systemic disease for which the clinical manifestations are complex and diverse." | ( Gao, Y; Gao, Z; Hu, Z; Li, X; Liu, J; Peng, T; Zhen, J, 2018) |
| "Systemic lupus erythematosus is an autoimmune disease characterized by overproduction of type 1 IFN that causes multiple organ dysfunctions." | ( Allegood, JC; Aparna, JS; Harikumar, KB; James, S; Lankadasari, MB; Li, QZ; Mohammed, S; Spiegel, S; Vineetha, NS, 2019) |
| "Vasculopathy in systemic lupus erythematosus is a rare form of vascular involvement characterized by non-inflammatory vascular injury with the accumulation of immune complexes in the walls of the arteries, resulting in luminal narrowing." | ( Morinobu, A; Onishi, A; Waki, D, 2019) |
| "Systemic lupus erythematosus is a systemic autoimmune inflammatory disease with a broad spectrum of clinical presentations." | ( Bhatnagar, A; Pannu, N, 2020) |
| "Systemic lupus erythematosus is a multisystem autoimmune disease." | ( Bhatnagar, A; Pannu, N, 2020) |
| "Paediatric systemic lupus erythematosus is a rare autoimmune disease with a wide spectrum of clinical presentation in different populations." | ( Chan, EWL; Lim, SC; Tang, SP, 2020) |
| "Systemic Lupus Erythematosus is an autoimmune disease with symptoms pervasive to all organ systems." | ( Anupam, K; Bhatnagar, A; Gautam, P; Kaushal, J; Sharma, A; Tandon, A, 2020) |
| "Systemic lupus erythematosus is an autoimmune disease characterized by an overproduction of autoantibodies resulting from dysregulation in multiple immune cell types." | ( Abboud, G; Li, W; Morel, L; Teng, X; Wang, H; Ye, S, 2021) |
| "Systemic lupus erythematosus is a prototypic autoimmune disorder that primarily affects women of childbearing age and is associated with a loss of self-tolerance, autoreactive B and T lymphocytes, and the production of autoantibodies, especially to nuclear components." | ( Jones, KE; Kalusche, WJ; McClung, DM; Ryan, MJ; Taylor, EB, 2021) |
| "Systemic lupus erythematosus is a multi-organ inflammatory autoimmune disease; immune complexes are part of the pathogenesis, but not entirely responsible." | ( Akutsu, Y; Mori, M; Segawa, Y; Shimbo, A; Shimizu, M; Yamazaki, S, 2021) |
| "Systemic lupus erythematosus is a chronic inflammatory disease, in which treatment is still limited due to suboptimal efficacy and toxicities associated with the available therapies." | ( Banach, M; Bujak, A; Dubiel, K; Dulak-Lis, M; Gala, K; Gunerka, P; Hucz-Kalitowska, J; Kędzierska, U; Miszkiel, J; Mroczkiewicz, M; Pieczykolan, JS; Stypik, B; Szymczak, K; Wieczorek, M; Zygmunt, BM, 2021) |
| "Systemic lupus erythematosus is a rare autoimmune disorder, with the prevalence in Asia ranging from 30 to 50/100,000." | ( Dissanayaka, P; Jayawickreme, KP; Perera, L; Subasinghe, S; Weerasinghe, S, 2021) |
| "Systemic lupus erythematosus is a chronic inflammatory autoimmune disease that has various manifestations." | ( Ai, J; Guo, Q; Liu, D; Qu, Y; Wang, D; Wen, J; Yu, Q; Zhou, Q, 2022) |
| "Systemic lupus erythematosus is an autoimmune multisystem disease; renal affection is one of its most common manifestations." | ( Abdelaziz, TS; Fayad, T; Fayed, A; Hammad, H; Mahmoud, GA; Rakha, NK, 2023) |
| "Systemic lupus erythematosus is an autoimmune multisystem disease; renal affection is one of its most common manifestations." | ( Abdelaziz, TS; Fayad, T; Fayed, A; Hammad, H; Mahmoud, GA; Rakha, NK, 2023) |
| "Systemic lupus erythematosus is an autoimmune multisystem disease; renal affection is one of its most common manifestations." | ( Abdelaziz, TS; Fayad, T; Fayed, A; Hammad, H; Mahmoud, GA; Rakha, NK, 2023) |
| "Systemic lupus erythematosus is an autoimmune multisystem disorder in which ocular involvement such as acute ischemic optic neuropathy is a rare manifestation." | ( Khan, AH; Mahmud, R; Moniruzzaman, M; Rahman, MM; Sayeed, SKJB, 2023) |
| "Systemic lupus erythematosus is an autoimmune disease associated with serious complications and high costs." | ( Duarte-Rey, C; Gaviria-Mendoza, A; González-Rangel, A; Machado-Alba, JE; Machado-Duque, ME, 2023) |
| "The etiology of systemic lupus erythematosus is complex and incurable." | ( Chen, Q; Hua, C; Li, LW; Shi, YZ; Xiao, XY; Zheng, H, 2023) |
| "Systemic lupus erythematosus is a debilitating autoimmune disease characterized by uncontrolled activation of adaptive immunity, particularly B cells, which predominantly affects women in a 9 to 1 ratio compared to men." | ( Diao, L; Jensen, F; Valeff, NJ; Ventimiglia, MS, 2023) |
| Excerpt | Reference |
|---|
| "A reversible syndrome resembling systemic lupus erythematosus and induced by hydralazine hydrochloride therapy is a well-recognized phenomenon in adults but does not seem to have been reported in children." | ( Irias, JJ, 1975) |
| "Two patients with systemic lupus erythematosus complicated with lupus nephritis were treated with levamisole, an immunomodulator." | ( Hisano, G; Ogawa, K; Sano, T; Tsubura, E, 1979) |
| "Thirteen patients with active systemic lupus erythematosus (SLE) and biopsy proven nephropathy were treated with thiamphenicol for two weeks." | ( Richmond, DE, 1979) |
| "Fourteen patients with active systemic lupus erythematosus (SLE) have been treated with plasmapheresis at a rate of two litres daily on three to four days per week, over a period of two to three weeks." | ( Bacon, PA; Bothamley, J; Cumming, RH; Davis, P; Evers, J; Fraser, ID; Hughes, GR; Jones, JV; Tribe, CR, 1979) |
| "It may also be secondary to systemic lupus erythematosus, rheumatoid arthritis, acute severe renal failure, severe nutritional deficiency, or diverse neoplasms, and may remit with treatment of the primary condition." | ( Krantz, SB, 1976) |
| "A 25-year-old Oriental woman developed systemic lupus erythematosus during a course of treatment with carbamazepine for long-standing idiopathic epilepsy." | ( Imamura, S; Kanoh, T; Takahashi, C; Takigawa, M, 1976) |
| "Features of both systemic lupus erythematosus and scleroderma developed in a young Chinese girl while on multiple anticonvulsant therapy." | ( Chan, HL; Teoh, PC, 1975) |
| "Forty-nine patients with systemic lupus erythematosus (SLE) during childhood and adolescence presenting over a period of 17 years were followed during treatment with prednisone and azathioprine." | ( Blau, EB; Burke, BA; Fish, AJ; Michael, AF; Vernier, RL; Westberg, NG, 1977) |
| "A patient with systemic lupus erythematosus (SLE) and a patient with an immune complex disease resembling Goodpasture's syndrome were treated with cyclophosphamide, prednisone and repeated plasma exchanges." | ( Eknoyan, G; Gyorkey, F; Hersh, EM; McCredie, KB; Reisberg, MA; Rossen, RD; Sharp, JT; Suki, WN, 1977) |
| "Drug-induced systemic lupus erythematosus (SLE)-like syndromes in children are most commonly associated with the administration of ethosuximide, diphenylhydantoin, and trimethadione." | ( Fishman, L; Hanson, V; Singsen, BH, 1976) |
| "criteria for the diagnosis of systemic lupus erythematosus, 43 were selected for study because each had been treated for at least two years with antimalarials, but had not received antimalarials for at least one subsequent year." | ( Gresham, GE; Rothfield, NF; Rudnicki, RD, 1975) |
| "A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; Tegretol) used against benign Rolandic epilepsy." | ( Kanno, T; Kasukawa, R; Kazuta, Y; Miyata, M; Nishimaki, T; Sato, Y, 1992) |
| "This suggests that systemic lupus erythematosus (SLE) is more common in elderly people than was originally thought and is a potentially treatable cause of organic brain disorder." | ( Bendall, P; Byrne, EJ; Dennis, MS; Hopkinson, N, 1992) |
| "The course of 6 patients with childhood systemic lupus erythematosus was analysed with emphasis on the effect and limitation of intravenous methylprednisolone pulse therapy in the long-term follow-up." | ( Aihara, Y; Ibe, M; Kosuge, K; Kuriyama, T; Mitsuda, T; Mori, T; Shimizu, H; Yokota, S, 1992) |
| "Ten patients with systemic lupus erythematosus (SLE) were treated with ECP in an open clinical trial." | ( Graninger, W; Knobler, RM; Lindmaier, A; Smolen, JS; Trautinger, F, 1992) |
| "A prospective study of systemic lupus erythematosus (SLE) patients under high doses of corticosteroid therapy (greater than 30 mg/day prednisolone) for a five-year period elucidated some risk factors of avascular necrosis of the femoral head (ANFH)." | ( Komazawa, T; Ono, K; Tohjima, T, 1992) |
| "We report a case of systemic lupus erythematosus (SLE) in a young woman who presented a serious encephalopathy with respiratory distress and coma, after arbitrary interruption of oral corticosteroid therapy when her first pregnancy ended in abortion." | ( Bonavita, V; Di Iorio, G; Migliaresi, S; Picillo, U; Santanelli, P, 1992) |
| "A 49 year old white woman with systemic lupus erythematosus and bronchiolitis obliterans was treated with prednisone (1 mg/kg daily), which led to a transitory improvement in pulmonary status." | ( Cormier, C; Godeau, B; Menkes, CJ, 1991) |
| "Seven patients with systemic lupus erythematosus (SLE), persistent thrombocytopenia (TP), in whom it was considered undesirable to institute an increase in steroid or immunosuppressive agents, were treated with danazol." | ( Wong, KL, 1991) |
| "Twelve patients suffering from systemic lupus erythematosus (SLE) were treated with piroxicam (Hotemin-EGIS) for 9-18 (mean: 13." | ( Gergely, P, 1991) |
| "Both patients were treated for systemic lupus erythematosus; one patient was treated with 400 to 800 mg of hydroxychloroquine per day (6." | ( Berson, EL; Gaudio, AR; Kini, MM; Sandberg, MA; Weiner, A, 1991) |
| "There were 9 patients (6 with systemic lupus erythematosus, 2 with sarcoidosis and one with polymyositis), who were treated with prednisolone (daily period) and subsequently put on an alternate-day regimen (alternate-day period)." | ( Adachi, K; Fuwa, Y; Goshima, E; Miura, K; Yamakita, N; Yasuda, K, 1991) |
| "We describe 2 patients with systemic lupus erythematosus (SLE) who developed an acute psychosis and a cerebrovascular accident after pulse methylprednisolone therapy." | ( Leibovici, L; Wysenbeek, AJ; Zoldan, J, 1990) |
| "Bone affectation in systemic lupus erythematosus (SLE) is caused both by the disease itself and by the treatment used." | ( Atanes, A; Burson, JS; Galdo, F; Graña, J; Varela, J, 1990) |
| "We describe a 19 year old woman with systemic lupus erythematosus on corticosteroid therapy, who developed bilateral, multiple, gas-forming Salmonella enteritidis leg abscesses and osteomyelitis mimicking deep vein thrombosis." | ( Nussinovitch, N; Rosenthal, T; Shamiss, A; Thaler, M; Zissin, R, 1990) |
| "A 30-year-old woman, suffering from systemic lupus erythematosus and treated with azathioprine and methyl-prednisolone, developed seven molluscum contagiosum lesions of the upper part of her left calf." | ( Lachapelle, JM; Naert, F, 1989) |
| "Between 1976 and 1988, 7 patients with systemic lupus erythematosus (SLE) underwent splenectomy for severe peripheral thrombocytopenia (platelet count below 30,000/mm3) which had resisted corticosteroid therapy (n = 7), high-dose immunoglobulins (n = 4), vincristine (n = 2), danazol (n = 1), cyclophosphamide and plasma exchanges (n = 1)." | ( Bletry, O; Godeau, P; Guillevin, L; Langlois, P; Lê Thi Huong, D; Piette, JC; Raguin, G; Renou, P, 1989) |
| "21 patients with systemic lupus erythematosus induced by long-term treatment with hydralazine were investigated to see whether susceptibility to this syndrome was associated with deficiency of the classical pathway complement protein, C4." | ( Batchelor, JR; Chapel, H; Davey, NJ; Fielder, AH; Speirs, C, 1989) |
| "Thirty patients suffering from systemic lupus erythematosus (SLE) were treated with daily 20 mgs of piroxicam (Hotemin)." | ( Gergely, P, 1989) |
| "A 63-year-old man with systemic lupus erythematosus and selective IgA deficiency developed intractable diarrhoea the day after treatment with prednisone, 50 mg daily, was started." | ( Denison, H; Wallerstedt, S, 1989) |
| "We report a case of IBM associated with systemic lupus erythematosus and modest response of the myopathy to corticosteroid therapy." | ( Smith, TW; Yood, RA, 1985) |
| "Treatment of patients suffering from systemic lupus erythematosus with vitamin A (100,000 U daily for 2 weeks) resulted in an enhancement of antibody-dependent cell-mediated cytotoxicity, natural killer cell activity and blastogenic response to plant mitogens and interleukin-2 (IL-2)." | ( Bodó, I; Gergely, P; González-Cabello, R; Vien, CV, 1988) |
| "Severe systemic lupus erythematosus affecting the kidney or central nervous system may lead to organ failure or death despite treatment with high doses of corticosteroids." | ( Bohlke, P; Dunne, R; Fox, DA; Golbus, J; McCune, WJ; Zeldes, W, 1988) |
| "Twenty one patients with severe systemic lupus erythematosus (SLE) were treated with three daily infusions of either 100 mg or 1 g of methylprednisolone on a randomised double blind basis." | ( Edwards, JC; Isenberg, DA; Snaith, ML, 1987) |
| "Treatment of hypertension in systemic lupus erythematosus (SLE) may be complicated by unwanted immunologic vascular and renal side effects of drugs." | ( Bursztyn, M; Many, A; Rosenthal, T, 1987) |
| "We report a young woman with systemic lupus erythematosus complicated by pseudotumor cerebri which resolved with high dosage corticosteroid therapy." | ( Goodwin, JA; Levinson, DJ; Parnass, SM; Patel, DV; Reinhard, JD, 1987) |
| "Two patients with severe systemic lupus erythematosus, who had not responded to conventional therapy, were treated with plasmapheresis and subsequent pulse cyclophosphamide." | ( Euler, HH; Löffler, H; Schroeder, JO, 1987) |
| "A case of systemic lupus erythematosus (SLE) associated with Sjögren's syndrome had extremely low serum triiodothyronine (T3) with normal levels of serum thyroxine (T4) measured by single antibody radioimmunoassays (RIAs) and thyroid stimulating hormone (TSH) during steroid treatment." | ( Kojima, M; Komaki, T; Miura, K; Nakamura, S; Sakata, S; Suzuki, S; Torigai, K, 1987) |
| "In two patients with systemic lupus erythematosus, conventional therapy was considered to have failed because of persistent disease activity and unacceptable side effects." | ( Ben-Chetrit, E; Braverman, A; Eliakim, M; Fuks, Z; Gross, DJ; Slavin, S; Weshler, Z, 1986) |
| "A 31-year-old woman with systemic lupus erythematosus (SLE) taking chronic corticosteroid therapy developed Kaposi's sarcoma." | ( Barth, WF; Fulenwider, A; Greenfield, DI; Trinh, P, 1986) |
| "A 32-year-old man with systemic lupus erythematosus controlled by steroid therapy developed multifocal cutaneous abscesses caused by Mycobacterium scrofulaceum." | ( Egan, N; Murray-Leisure, KA; Weitekamp, MR, 1987) |
| "This report describes two cases of systemic lupus erythematosus (SLE) treated with immunosuppressive agents." | ( Goldberg, J; Paolozzi, FP, 1985) |
| "Fourteen patients with systemic lupus erythematosus had splenectomies done between 1960 and 1982 for treatment of severe thrombocytopenia." | ( Greipp, PR; Hall, S; McCormick, JL; McKenna, CH; Michet, CJ, 1985) |
| "A 19-year-old man with untreated systemic lupus erythematosus had an acute myocardial infarction." | ( Hattori, R; Kawai, C; Sakaguchi, K; Takatsu, Y; Yui, Y, 1985) |
| "A 10-year-old boy with systemic lupus erythematosus exhibiting prominent features of dermatomyositis has been treated with 600 mg prednisolone intravenously per day on 3 consecutive days." | ( Schreiber, G; Wollina, U, 1985) |
| "A 20-year-old patient had systemic lupus erythematosus and extensive generalized discoid disease that failed to respond to conventional treatment with topical steroids and high doses of hydroxychloroquine sulfate (Plaquenil)." | ( Caughman, SW; Klippel, JH; Tsokos, GC, 1985) |
| "A 62-year-old woman who developed systemic lupus erythematosus 6 years following chemotherapy for malignant lymphoma is reported." | ( Berliner, S; Galili, N; Mor, C; Pinkhas, J; Sidi, Y; Weinberger, A, 1985) |
| "Acute anuric renal failure complicating systemic lupus erythematosus does not usually respond to treatment with corticosteroids and immunosuppressive agents." | ( Brancaccio, D; Imbasciati, E; Ponticelli, C; Rivolta, E; Tarantino, A, 1974) |
| "26 patients with systemic lupus erythematosus (SLE) induced by treatment with the antihypertensive drug hydralazine were investigated to determine if predisposition to the toxic effect was associated with an HLA-DR antigen." | ( Aber, GM; Batchelor, JR; Bernstein, R; Bing, RF; Dollery, CT; Hughes, GR; Naish, PF; Russell, GI; Ryan, P; Tinoco, RM; Welsh, KI, 1980) |
| "The syndrome resembling systemic lupus erythematosus (SLE) associated with long-term treatment with hydralazine and isoniazid seems to be due to the drugs themselves rather than their metabolites." | ( Gill, EW; Sim, E; Sim, RB, 1984) |
| "Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis." | ( Essigman, WK, 1982) |
| "A 45-year-old female with systemic lupus erythematosus underwent liver biopsies twice during the period of cefazolin administration and a complication of cefazolin-induced toxic hepatitis was strongly suggested." | ( Tange, T, 1981) |
| "Thirty-nine patients with systemic lupus erythematosus (SLE) and diffuse proliferative glomerulonephritis have been enrolled in a multi-centre randomised controlled prospective study of chronic 4L plasma exchange therapy performed every three to four weeks." | ( Balfe, JW; Cattran, DC; Clark, WF; Lindsay, RM; Linton, AL; Williams, W, 1983) |
| "This system was used to treat systemic lupus erythematosus effectively." | ( Maeda, K; Narita, S; Ohbayashi, S; Saito, A; Sezaki, R; Shinzato, T; Tsuruta, Y; Usuda, M; Yamada, K; Yoshida, F, 1984) |
| "Eleven patients with active systemic lupus erythematosus, previously untreated, were studied to 1) determine the acute effect of corticosteroids on circulating immune complex (CIC) levels and 2) correlate the initial CIC profile with the development of organ system involvement." | ( Birchmore, DA; Boyd, RE; Davis, JS; Kaiser, DL; Young, AC, 1983) |
| "Seven patients with systemic lupus erythematosus (SLE) were treated with Danazol in a controlled study." | ( Agnello, V; Gelfand, J; Gell, J; Pariser, K; Turksoy, RN, 1983) |
| "Seven women with severe Systemic Lupus Erythematosus Nephritis were treated with Plasma Exchange, without any additional therapy with cytotoxic agents." | ( Bombardieri, S; Cioni, L; Fanara, G; Ferri, C; Gremignai, G; Migliorini, P; Moriconi, L; Vitali, C, 1983) |
| "A patient with systemic lupus erythematosus developed jaundice and biochemical evidence of hepatic dysfunction 3 wk after initiation of azathioprine therapy." | ( DePinho, RA; Goldberg, CS; Lefkowitch, JH, 1984) |
| "Tendon rupture in systemic lupus erythematosus (SLE) is a rare complication that appears to occur in patients receiving corticosteroid therapy." | ( Bassan, HM; Potasman, I, 1984) |
| "Two paediatric patients with systemic lupus erythematosus were treated with immunoglobulin G (IgG)." | ( Dopfer, R; Gaedicke, G; Kohne, E; Niethammer, D; Teller, WM, 1984) |
| "Two women with systemic lupus erythematosus who showed premenstrual flaring of the disease were treated with danazol, which resulted in clinical improvement." | ( Hughes, GR; Morley, KD; Parke, A, 1982) |
| "Four patients with systemic lupus erythematosus developed a nonpruritic vesiculobullous eruption that was unresponsive to high-dose systemic corticosteroid therapy." | ( Hall, RP; Katz, SI; Lawley, TJ; Smith, HR, 1982) |
| "Twenty patients with active systemic lupus erythematosus (SLE) were treated with methyl prednisolone pulse therapy (MPPT) and followed up for up to 24 weeks (mean 18 weeks)." | ( Isenberg, DA; Morrow, WJ; Snaith, ML, 1982) |
| "2 patients with systemic lupus erythematosus and mild renal functional impairment were treated with ibuprofen, one of the phenylproprionic nonsteroidal anti-inflammatory drugs." | ( Cohen, AH; Fong, HJ, 1982) |
| "Examination of 27 patients with systemic lupus erythematosus (SLE) before treatment showed an elevation of the serum level of lactic dehydrogenase (LDH) in 15 patients." | ( Horiguchi, T; Inoue, T; Kanayama, Y; Kato, N; Ohe, A; Shiota, K, 1981) |
| "Twelve patients with systemic lupus erythematosus and biopsy-proved diffuse proliferative glomerulonephritis were randomly allocated to a control group (to continue receiving conventional therapy only) or to a plasmapheresis group (to receive conventional therapy along with one 4-I plasma exchange a month)." | ( Barnes, CC; Cattran, DC; Chodirker, WB; Clark, WF; Lindsay, RM; Linton, AL, 1981) |
| "When six untreated female patients with systemic lupus erythematosus were compared with fifteen age-matched, corticosteroid-treated female patients, NK activity in the latter was significantly suppressed." | ( Gonda, N; Kano, S; Oshimi, K; Sumiya, M, 1980) |
| "A 21-year-old woman with systemic lupus erythematosus (SLE) had meningismus, conjunctivitis, lymphadenopathy, and elevation of liver function values following ibuprofen therapy." | ( Barth, WF; Ruppert, GB, 1981) |
| "Thirteen patients with systemic lupus erythematosus (SLE) without avascular necrosis and with long-term corticosteroid treatment and 12 healthy subjects were evaluated." | ( Bluemke, DA; Petri, M; Zerhouni, EA, 1995) |
| "The authors report a case of systemic lupus erythematosus in a hypogonadal male with Klinefelter's syndrome who was treated with testosterone in doses sufficient to normalize the serum level of this hormone to the adult male range." | ( Kovacs, WJ; Olsen, NJ, 1995) |
| "In the treatment of systemic lupus erythematosus (SLE) with acute CNS affections good results may be obtained with intravenous cyclophosphamide (CP) + methylprednisolone followed with long-term parenteral CP administration." | ( Bliziuk, OI; Ivanova, MM; Travkina, IV, 1995) |
| "A 46-year old woman with systemic lupus erythematosus (SLE) who had been treated with oral administration of prednisolone (7." | ( Igarashi, T; Ishigatsubo, Y; Motoji, K; Ohno, S; Ohta, S; Okubo, T; Shirai, A; Soga, T; Sumino, K; Takeshita, F, 1995) |
| "Ninety-two women with systemic lupus erythematosus treated with oral cyclophosphamide were studied to ascertain the prevalence and the factors associated with ovarian dysfunction." | ( Bosco, JJ; Wang, CL; Wang, F, 1995) |
| "Seven patients suffering from systemic lupus erythematosus (SLE) were treated by cyclosporin A (CSA) plus corticosteroids." | ( Gergely, P, 1994) |
| "We report a 49 years old woman with systemic lupus erythematosus and a WHO type IV nephropathy, treated with prednisone 1 mg/kg/day po and cyclophosphamide 1 g/month iv." | ( Guzmán, L; Neira, O; Wainstein, E, 1993) |
| "Two depressive patients with systemic lupus erythematosus (SLE) and cerebral infarction, while being treated with corticosteroid, are described." | ( Abe, K; Mizuki, T; Ohji, T; Terao, T, 1994) |
| "A case of systemic lupus erythematosus (SLE) complicated with hypopituitarism after steroid pulse therapy is reported." | ( Ebizuka, T; Hashimoto, H; Hirose, S; Ikeda, M; Kawano, T; Kobayashi, S; Tanaka, M, 1994) |
| "Survival of patients with systemic lupus erythematosus has increased with corticosteroid therapy." | ( Hoffman, R; Lethen, H; Maurin, N; Schöndube, FA; Sieberth, HG; Zunker, U, 1994) |
| "A man with systemic lupus erythematosus receiving chronic steroid therapy presented with headache, fever and panophthalmitis." | ( Cronstein, B; Goldman, R; Lewis, S, 1993) |
| "A patient with systemic lupus erythematosus and elevated cardiolipin antibody levels was given low-dose aspirin therapy prior to and throughout her third pregnancy to minimize the risk of miscarriage." | ( Chakravarty, K; Merry, P, 1993) |
| "We describe a patient with systemic lupus erythematosus and severe, treatment-resistant thrombocytopenia." | ( Hutchinson, GJ; Roach, BA, 1993) |
| "A case of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) associated with pulmonary cryptococcosis which was successfully treated with fluconazole (FCZ) and flucytosine (5-FC) is described." | ( Kano, S; Minato, N; Saito, K; Saito, T; Saku, N; Sato, M; Suzuki, N; Takeda, A, 1993) |
| "She had been diagnosed as systemic lupus erythematosus (SLE) in 1988 and treated with prednisolone at the dose of 5 mg a day." | ( Fukuda, T; Hosoya, Y; Makino, S; Motojima, S; Sato, M, 1995) |
| "A case of full blown systemic lupus erythematosus (SLE) was treated with steroid." | ( Bumpenboon, T; Chanchairujira, T; Insiripong, S, 1996) |
| "We describe the case of a patient with systemic lupus erythematosus, treated by corticosteroids, who presented during two successive pregnancies with serological reactivation of toxoplasmosis associated with fetal lesions." | ( Blanc, B; Boubli, L; Casta, M; Chagnon, C; Cravello, L; D'Ercole, C; Franck, J; Harle, JR; Leclaire, M, 1995) |
| "This observation shows that systemic lupus erythematosus may present with precapillary pulmonary hypertension, the conventional treatment of which may be successfully completed by steroid therapy." | ( Babuty, D; Cosnay, P; Fauchier, JP; Fauchier, L; Goupille, P; Marchal, C; Valat, JP, 1996) |
| "Therapy in pediatric systemic lupus erythematosus (SLE) is reviewed by examining the pediatric experience, including uncontrolled retrospective observations and case reports." | ( Silverman, E, 1996) |
| "Many patients with systemic lupus erythematosus (SLE) receive long-term treatment with azathioprine and prednisolone to control disease activity." | ( Abendroth, K; Hein, G; Oelzner, P; Stein, G, 1996) |
| "Life-threatening exacerbations of systemic lupus erythematosus can endanger the function of vital organ systems and require massive immunosuppressive treatment after the diagnostic delineation of the situation." | ( Graninger, W, 1996) |
| "12 patients with rapidly progressive systemic lupus erythematosus (SLE) combined with renal failure were treated for 6 months according to the following scheme: 3 consecutive procedures of plasmapheresis (60 ml/kg x 3), 3 consecutive pulse doses of cyclophosphamide (400 mg/m2 x 3), 3 prednisolone infusions (2 mg/kg x 3), oral cyclophosphamide (100-250 mg/day) and prednisolone (0." | ( Demin, AA; Demina, LM; Mamin, IV; Sentiakova, TN; Smirnov, VV, 1996) |
| "A patient with systemic lupus erythematosus (SLE) developed bilateral cytomegalovirus (CMV) retinitis and was treated with a total of 9 intravitreal ganciclovir injections at a dose of 400 micrograms/50 microliters in each eye under topical anesthesia." | ( Fujino, Y; Kaji, Y, 1997) |
| "The case of a patient with systemic lupus erythematosus and transverse myelitis, who presented a favourable clinical course following early treatment with high-dose corticoids, is reported." | ( Benito, P; Blanch, J; Campillo, MA; Márquez, MA; Martí, N; Pros, A, 1997) |
| "Treatment of systemic lupus erythematosus-related acute transverse myelitis remains controversial." | ( Habr, F; Wu, B, 1998) |
| "A woman with systemic lupus erythematosus developed severe myopathy after a septicemic episode, and her treatment before admission was hydroxychloroquine sulfate and prednisolone." | ( Richards, AJ, 1998) |
| "A 37-year-old patient with systemic lupus erythematosus, who had been treated with oral corticosteroids for 10 years, developed primary cutaneous nocardiosis." | ( Coppini, M; Ferdani, G; Folgaresi, M; Pincelli, C, 1998) |
| "We treated a 31-year-old woman with systemic lupus erythematosus, renal failure with nephrotic syndrome, and a long-standing seizure disorder, who developed severe hyperammonemia with a fatal outcome." | ( Amano, T; Ichikawa, H; Kawabata, K; Kushiro, M; Makino, H; Nagake, Y; Wada, J, 1998) |
| "In treating systemic lupus erythematosus, clinicians need to consider not only the organ involvement and the complications of therapy, but also associated conditions such as premature atherosclerosis and thrombosis." | ( Godfrey, T; Hughes, GR; Khamashta, MA, 1998) |
| "Central nervous system involvement in systemic lupus erythematosus (SLE) requires immediate treatment." | ( Corcia, P; Diot, E; Ferrandière, M; Giniès, G; Hazouard, E; Legras, A, 1998) |
| "Two studies of systemic lupus erythematosus show a nearly three-fold increased risk apparent after 2 or more years of hormone therapy." | ( Barrett-Connor, E, 1999) |
| "A patient with systemic lupus erythematosus (SLE) developed primary subcutaneous nocardiosis during steroid and cyclophosphamide therapy for diffuse proliferative glomerulonephritis." | ( Balbir-Gurman, A; Nahir, AM; Schapira, D, 1999) |
| "Ten patients with systemic lupus erythematosus (SLE) were treated with 1500-2000 mg mycophenolae mofetil (MMF) daily for a median observation time of 11." | ( Domschke, W; Gaubitz, M; Kern, P; Schorat, A; Schotte, H, 1999) |
| "We report a pregnant woman with systemic lupus erythematosus and recurrent venous thromboembolism who suffered from heparin-induced thrombocytopenia type II while treated with dalteparin sodium." | ( Geberth, M; Harenberg, J; Heene, DL; Hoffmann, U; Huhle, G, 2000) |
| "We treated 10 patients with systemic lupus erythematosus fulfilling ACR criteria with CYS for at least 12 months and followed renal function, serologic activity and SLEDAI scores." | ( Hallegua, D; Klinenberg, JR; Metzger, AL; Rinaldi, RZ; Wallace, DJ, 2000) |
| "The development of systemic lupus erythematosus (SLE)-related syndromes during treatment with sulphasalazine has been described and demonstrated to be influenced by genetic factors." | ( Forslid, J; Gröndal, G; Gunnarsson, I; Hassan Bakri, A; Klareskog, L; Larsson, P; Nordmark, B; Ringertz, B, 2000) |
| "The effect of systemic lupus erythematosus (SLE) treatment drugs on PKC (protein kinase C) activity and cell growth was studied using GI-101A breast tumor cells." | ( Fernandez, Y; Ramakrishnan, R; Rathinavelu, A, 2000) |
| "We tested mood states in patients with systemic lupus erythematosus (SLE) treated with the prolactin-lowering drug, bromocriptine." | ( McMurray, RW; Nelson, W; Parker, JC; Smarr, KL; Walker, SE; Weidensaul, DN, 2000) |
| "The patient with systemic lupus erythematosus (SLE) is at risk of osteoporosis through several factors: the inflammatory disease itself, disease-related co-morbidity, and its treatment." | ( Keen, RW; Sen, D, 2001) |
| "A rare manifestation of systemic lupus erythematosus (SLE) is cerebral venous sinus thrombosis (CVST), in which early diagnosis and aggressive therapy are of prime importance for favorable outcome." | ( Kang, HR; Kang, YM; Kim, JH; Kim, NS; Kim, SW; Lee, JM; Lee, MK; Nam, EJ; Rho, HJ, 2001) |
| "Corticosteroids used for treatment of systemic lupus erythematosus (SLE) are potent apoptosis inducers." | ( Ho, CY; Lam, WK; Li, EK; Wong, CK, 2001) |
| "To clarify the clinical features of systemic lupus erythematosus (SLE) complicated with pulmonary hypertension (PH) and to evaluate the efficacy of immunosuppressive treatment." | ( Hara, M; Harigai, M; Kamatani, N; Kawaguchi, Y; Tanaka, E; Tanaka, M, 2002) |
| "To study the outcome of pregnancy with systemic lupus erythematosus (SLE) treated by DNA immunoabsorbent therapy." | ( Chen, C; Li, G; Li, Y; Li, Z; Lin, E; Wang, A; Yu, Y; Zhao, Y, 2002) |
| "The rash of systemic lupus erythematosus (SLE) is usually treated with topical corticosteroids, but prolonged use causes adverse cutaneous side-effects." | ( Kanekura, T; Kanzaki, T; Miyoshi, H; Terasaki, K; Yoshii, N, 2003) |
| "She was diagnosed as having systemic lupus erythematosus at the age of 21 years and had been receiving systemic steroid treatment (5 mg prednisolone/day)." | ( Furue, M; Koga, T; Moroi, Y; Terao, H; Urabe, K, 2003) |
| "Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide." | ( Becker, A; Neuen-Jacob, E; Ostendorf, B; Richter, JG; Schneider, M; Specker, C; Stoll, G, 2003) |
| "Here we present a case of systemic lupus erythematosus complicated by HPS that was successfully treated with liposteroid in addition to an oral corticosteroid and intravenous high-dose cyclophosphamide therapy." | ( Funauchi, M; Kanamaru, A; Kinoshita, K; Nozaki, Y; Ohno, M; Yamagata, T, 2003) |
| "The case notes of patients with systemic lupus erythematosus (SLE) with class 4 nephritis and who were given standard pulse intravenous cyclophosphamide therapy during the period 1990-2000 were retrospectively reviewed." | ( Bhagwandass, A; Sargeant, LA; Shah, D; Williams, W, 2003) |
| "Twenty-nine patients with systemic lupus erythematosus were treated with a new synthetic unsaturated prednisolone derivative, triamcinolone, for as long as 11 months." | ( DUBOIS, EL, 1958) |
| "She was diagnosed with systemic lupus erythematosus in September, 1996 and had been on a regular glucocorticoid therapy since then." | ( Hirata, D; Isoda, N; Kamata, Y; Kamimura, T; Kanai, N; Masuyama, J; Minota, S; Yoshio, T, 2003) |
| "Currently, systemic lupus erythematosus therapy is suboptimal due to adverse effects of immunosuppressants, particularly corticosteroids." | ( Jusko, WJ; Kamal, MA, 2004) |
| "After gene therapy, clinical signs of systemic lupus erythematosus were reduced dramatically: the anti-nuclear antibody titers and urine protein/creatinine ratios were recovered to normal values, and the skin regained its normal histological features." | ( Chae, YJ; Choi, EW; Kim, DY; Lee, CW; Lee, H; Shin, IS; Youn, HY, 2005) |
| "Patients with systemic lupus erythematosus (SLE) have an increased susceptibility to TB because of their intrinsic immunocompromised state and the use of corticosteroid therapy." | ( Chan, TM; Lau, CS; Lo, Y; Mok, MY; Wong, WS, 2005) |
| "A diagnosis of systemic lupus erythematosus was made and oral administration of 60 mg/day prednisolon was started on May 10." | ( Fujino, MA; Katoh, K; Kawai, T; Kudo, M; Okouchi, A; Shoda, M; Tominaga, S, 2005) |
| "Cyclophosphamide (CYC) therapy for systemic lupus erythematosus (SLE), a disease predominantly affecting women of childbearing age, causes an unacceptably high incidence of irreversible premature ovarian failure (POF)." | ( Christman, GM; Marder, W; McCune, WJ; Ognenovski, V; Somers, EC, 2005) |
| "Twenty-six patients with persistent systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), primary Sjögren's syndrome (pSS), or systemic sclerosis (SSc) who had been treated unsuccessfully with conventional treatment were enrolled in the trial in Peking Union Medical College Hospital from September 1999 to June 2004." | ( Dong, Y; Leng, XM; Li, TS; Shen, T; Situ, H; Tang, FL; Zeng, XF; Zhang, FC; Zhao, Y; Zhao, YQ; Zhou, DB, 2005) |
| "We report a 33-year-old woman with systemic lupus erythematosus undergoing immunotherapy infected with combined invasive pulmonary aspergillosis and pulmonary cryptococcosis diagnosed by video-assisted thoracic surgery lung biopsy and she was successfully treated as a result of early diagnosis and treatment." | ( Chiang, PC; Huang, CC; Huang, SF; Lee, CH; Lin, CM; Liu, HP; Tsai, YH, 2006) |
| "A 39-year-old female patient with systemic lupus erythematosus was treated with terbinafine for onychomycosis." | ( Cetkovská, P; Pizinger, K, 2006) |
| "In treating pediatric patients with systemic lupus erythematosus (SLE), it is necessary to quickly attain remission to avoid sequelae in various organs and to maintain it over a long period." | ( Fujita, T; Iijima, K; Kamioka, I; Matsuo, M; Nakanishi, K; Nozu, K; Tanaka, R; Yoshikawa, N; Yoshiya, K, 2006) |
| "The patient had systemic lupus erythematosus and was treated with corticosteroids." | ( Li, RY; Yu, J, 2006) |
| "We describe a patient with systemic lupus erythematosus and LAHPS in whom successful treatment of central nervous system bleeding due to severe factor II deficiency was followed by a major thromboembolic complication." | ( Rich, E; Senécal, JL; Vinet, E, 2006) |
| "We describe 28 patients with systemic lupus erythematosus (SLE), between 1990 and 2005, whose initial biopsy (Bx1) showed PLN and who received nine monthly doses of intravenously administered cyclophosphamide (CYP) (500-750 mg/m(2) up to 1 g to maintain their absolute neutrophil count (ANC) > 3,000)." | ( Askenazi, D; De Guzman, M; Hicks, MJ; Kale, A; Kamdar, A; Minta, A; Myones, B; Perez, M; Warren, R, 2007) |
| "She had systemic lupus erythematosus and interstitial pneumonia for 17 years, treated with prednisolone and azathioprine." | ( Manabe, T; Shiomi, T; Yamamoto, T, 2007) |
| "Nine patients with systemic lupus erythematosus who had lupus nephritis resistant to previous treatment with glucocorticoids and immunosuppressants other than CsA were enrolled in a prospective, open-label study." | ( Amano, K; Kameda, H; Nagasawa, H; Ogawa, H; Sekiguchi, N; Takei, H; Takeuchi, T; Tsuzaka, K, 2007) |
| "Treatment of children with systemic lupus erythematosus (SLE) is challenging." | ( Adams, A; Lehman, TJ; Macdermott, EJ, 2007) |
| "We describe a 38-year-old woman with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) who developed two symmetric paramalleolar ulcers with similar diameters, depths and borders, that were successfully treated with photodynamic therapy with 5-aminolevulinic acid (ALA-PDT)." | ( Monti, M; Motta, S, 2007) |
| "In 2001, she was diagnosed with systemic lupus erythematosus (SLE) and treated with prednisolone and ciclosporin." | ( Hagiharai, K; Hirano, T; Kawai, M; Kawase, I; Kuwahara, Y; Ogata, A; Shima, Y; Tanaka, T; Yamadori, T; Yoshizaki, K, 2007) |
| "In murine models of systemic lupus erythematosus (SLE), administration of either prolactin or estradiol (E2) increases autoimmunity, and there is evidence that elevated prolactin in response to E2 administration may contribute substantially to E2 effects." | ( Butfiloski, EJ; Roberts, SM; Sobel, ES; Wang, F, 2007) |
| "Even though no new treatment for systemic lupus erythematosus (SLE) has been approved in over 40 years, the treatment possibilities have expanded decisively in this time." | ( Fischer-Betz, R; Schneider, M, 2007) |
| "Since systemic lupus erythematosus (SLE) is associated with platelet activation and increased cardiovascular mortality, we compared thromboxane and prostacyclin biosynthesis in patients with SLE and control subjects, and measured inhibition of thromboxane excretion in aspirin-treated subjects." | ( Avalos, I; Borntrager, H; Chung, CP; Milne, GL; Morrow, JD; Oeser, A; Raggi, P; Solus, J; Stein, CM, 2007) |
| "We present a case of systemic lupus erythematosus with symptomatic sensorineural hearing loss which was successfully treated with azathioprine, as assessed both clinically and radiologically." | ( Khalidi, NA; Rebello, R; Robertson, DD, 2008) |
| "A 53-year-old man with systemic lupus erythematosus who was receiving chronic low-dose prednisone treatment developed proptosis of the right eye." | ( Chen, CS; Eberhart, C; Lane, A; Miller, NR, 2008) |
| "At the time of her initial diagnosis of systemic lupus erythematosus, she had declined treatment, preferring to explore complementary medical therapies." | ( Greig, DE; Ludgate, MW, 2008) |
| "Case 2 had a history of systemic lupus erythematosus and rheumatoid arthritis, treated with hydroxychloroquine for 1." | ( Ferringer, T; Lountzis, NI; Puri, PK; Tyler, W, 2008) |
| "This case of PML in a patient with systemic lupus erythematosus on supra-therapeutic doses of methotrexate emphasises that CNS infection is an important diagnostic consideration before empiric treatment with immunosuppresants for NSLE." | ( Chin, S; Eskandari, R; Frech, T; Shprecher, D; Steffens, J, 2008) |
| "A 47-year-old woman with systemic lupus erythematosus presented with a history of radical hysterectomy and pelvic lymph node dissection for cervical cancer Ia and brachytherapy for vaginal recurrence." | ( Kang, S; Kim, M; Kim, SK; Lim, MC; Park, SY; Seo, SS, 2009) |
| "Except in the treatment of systemic lupus erythematosus with renal involvement, controlled studies with mycophenolate mofetil (MMF) are lacking in other autoimmune and inflammatory systemic diseases." | ( Bandelier, C; Finckh, A; Gabay, C; Genevay, S; Guerne, PA, 2009) |
| "We report the case of a patient with systemic lupus erythematosus (SLE) who first revealed hemophagocytic syndrome (HPS), which was treated successfully with glucocorticoid and intravenous cyclophosphamide." | ( Arai, S; Fukuda, T; Hanaoka, R; Kamiya, K; Kumano, K; Kurasawa, K; Maezawa, R, 2010) |
| "In patients with systemic lupus erythematosus (SLE) metabolic alterations are often observed, which may be due to either the disease, the genetic background or the treatment." | ( Bianco, NE; De Sanctis, JB; Garmendia, JV; Rivas, L; Zabaleta, M, 2009) |
| "Patients with systemic lupus erythematosus (SLE) are susceptible to the development of lymphoproliferative disorders and postulated causes include intrinsic defects in immune surveillance and iatrogenic administration of immunosuppressants." | ( Mok, MY; Trendell-Smith, NJ; Tsang, HH; Wu, AK, 2010) |
| "Fifty-two patients with systemic lupus erythematosus, 13 with active lupus nephritis, eight with thrombocytopenia, three with leukocytopenia, 25 with severe musculoskeletal involvement and three with skin involvement) refractory to conventional therapy were treated with anti-CD20 treatment (rituximab; MabThera, Roche) plus ongoing immunosuppressive treatment." | ( Beltran-Castillo, A; Garcia-Carrasco, M; Gonzalez, L; Graillet, D; Jimenez-Hernandez, M; Lopez-Colombo, A; Mendoza-Pinto, C; Pineda-Almazana, A; Rojas-Rodriguez, J; Sandoval-Cruz, M; Soto-Vega, E; Zamudio-Huerta, L, 2010) |
| "Maintenance therapy of severe pediatric systemic lupus erythematosus (SLE) usually consists of azathioprine and prednisone ." | ( Amann, K; Benz, K; Dittrich, K; Dötsch, J; Ross, S, 2009) |
| "Here, we report a case of systemic lupus erythematosus in a 13-year-old girl who developed the disease 3 years after thymectomy performed for the treatment of myasthenia gravis." | ( Abdulwahed, SR; Al Bshabshe, AA; Alzahrani, MA; Assiri, A; Dwedar, A; Hussein, MR; Omar, HA; Shalaby, M, 2010) |
| "The diagnosis of systemic lupus erythematosus and Sjögren's syndrome was made and treatment with glucocorticoid pulse followed by oral glucocorticoid was started." | ( Kimura, H; Matsuyama, Y; Minota, S; Nagashima, T; Onishi, S; Yoshio, T, 2010) |
| "A 23-year-old man (Case 1) with systemic lupus erythematosus developed rapid and severe vision loss, generalized neurologic decline, and eventual death after administration of fludarabine before stem cell transplantation." | ( Bishop, RJ; Caruso, R; Chan, CC; Cunningham, D; Ding, X; Heller, CK; Illei, G; Pavletic, S, 2010) |
| "A 41-year-old man with systemic lupus erythematosus (SLE) developed hyponatremia induced by SIADH after administration of tacrolimus (0." | ( Hasegawa, H; Hashimoto, K; Kawamoto, Y; Kohno, M; Matsumoto, T; Murakami, S; Nanba, C; Sada, E; Suemori, K; Yasukawa, M, 2011) |
| "A 36-year-old man with underlying systemic lupus erythematosus complicated by autoimmune hemolytic anemia underwent immunosuppressive treatment." | ( Fujisaki, T; Kubo, T; Muta, T; Nakanishi, H; Yokota, E; Yoshitomi, R, 2010) |
| "The outcome of systemic lupus erythematosus (SLE) has dramatically improved since the introduction of corticosteroids; however, although many regimens of treatment have been supplemented, the mortality has not improved further." | ( Dissaneewate, P; McNeil, E; Vachvanichsanong, P, 2011) |
| "We report a patient with systemic lupus erythematosus (SLE) who developed progressive emaciation and postprandial abdominal pain with a 27-year history of corticosteroid treatment." | ( Fukui, D; Ikeda, S; Kurozumi, M; Matsuda, M; Miyazaki, D; Sano, K; Shimojima, Y; Tazawa, K; Tojo, K, 2010) |
| "The outcome of systemic lupus erythematosus (SLE) is largely influenced by the existence of lupus nephritis (LN), and its histologic classification guides the treatment and prognosis of SLE." | ( Ahn, JK; Cha, HS; Huh, WS; Hwang, J; Kim, HJ; Kim, YG; Koh, EM; Lee, J; Lee, YS; Oh, JM; Seo, J, 2012) |
| "Treatment of patients with Systemic Lupus Erythematosus (SLE) who have active disease refractory to current therapeutic strategies continues to be a real challenge." | ( Amoura, Z; Arnaud, L; Costedoat-Chalumeau, N; Zahr, N, 2011) |
| "Despite aggressive treatment for systemic lupus erythematosus (SLE) with high-dose glucocorticoids and immunosuppressive agents, a significant proportion of patients persist with activity or relapse." | ( Forero, E; Márquez, JD; Mestra, L; Pinto, LF; Prieto, C; Velásquez, CJ, 2011) |
| "The aim of our study was to investigate systemic lupus erythematosus (SLE) related protein-losing enteropathy (PLE) in the following areas: clinical features, laboratory, endoscopic and imaging characteristics, treatment and outcome." | ( Law, ST; Li, KK; Ma, KM, 2012) |
| "Current therapies for treating systemic lupus erythematosus (SLE) mainly rely upon nonspecific and toxic immunosuppression by corticosteroids and cytotoxics." | ( Bosch, X; Khamashta, MA; Ramos-Casals, M, 2012) |
| "Current treatments for systemic lupus erythematosus (SLE) are effective in reducing morbidity and mortality but are not specific and have severe adverse effects." | ( Asher, I; Bezalel, S; Elbirt, D; Sthoeger, ZM, 2012) |
| "Treatment of thrombocytopenia in systemic lupus erythematosus (SLE) is considered in cases of current bleeding, severe bruising, or a platelet count below 50,000/µL." | ( Chung, SJ; Kang, MI; Kang, Y; Lee, SK; Lee, SW; Park, HJ; Park, YB, 2013) |
| "Patients with systemic lupus erythematosus (SLE) display reduced numbers and functions of invariant natural killer T (iNK T) cells, which are restored upon treatment with corticosteroids and rituximab." | ( Halder, RC; Kim, PJ; Singh, RR; Yang, JQ, 2013) |
| "We describe a patient with systemic lupus erythematosus diagnosed with simultaneous cryptococcal and TB meningitis who had a poor response to intravenous liposomal amphotericin B and fluconazole, but was successfully treated with intraventricular amphotericin B, in addition to anti-TB therapy." | ( Arslan, F; Mert, A; Mete, B; Ozaras, R; Ozkara, C; Ozturk, R; Saltoglu, N; Tabak, F; Vanli, E, 2016) |
| "A 57-year-old woman with systemic lupus erythematosus and Sjögren syndrome presented with blue-grey hyperpigmentation of the face, upper back, and dorsal aspects of the feet after seven years of therapy with hydroxychloroquine." | ( Boyd, KP; McLellan, B; Meehan, SA; Mir, A, 2013) |
| "For patients with refractory systemic lupus erythematosus (SLE), current medications are insufficient to control their condition, and new treatments are necessary." | ( Chuan, W; Wu-qing, W; Zhu-wen, Y; Zuo, L, 2014) |
| "A young woman with systemic lupus erythematosus (SLE) associated with interventricular septal hypertrophy exhibited a high pressure gradient between the ascending aorta and left ventricular outflow tract as well as significant systolic anterior motion (SAM) and mitral regurgitation (MR) during high-dose prednisone treatment." | ( He, B; Jiang, M; Pu, J; Shen, XD, 2014) |
| "Previous thrombosis, diagnosis of systemic lupus erythematosus (SLE) and triple antiphospholipid (aPL) antibody positivity have recently been found to be independent factors associated to pregnancy failure during conventional therapy in women with antiphospholipid syndrome (APS)." | ( Alijotas-Reig, J; Andreoli, L; Bertero, MT; Bremme, K; Brucato, A; Canti, V; Caramaschi, P; De Carolis, S; Del Ross, T; Di Poi, E; Galeazzi, M; Gerosa, M; Maina, A; Mekinian, A; Meroni, PL; Mosca, M; Ramoni, V; Ruffatti, A; Salvan, E; Tincani, A; Trespidi, L, 2014) |
| "Treatment of systemic lupus erythematosus (SLE), a chronic inflammatory disease, involves the long-term use of immunosuppressive agents with significant side effects." | ( Gao, J; Guo, L; Guo, W; Liu, W; Lu, T; Luo, Q; Shen, Y; Sun, Y; Wu, X; Xu, Q, 2015) |
| "To conduct a national survey of systemic lupus erythematosus (SLE) patients treated with mycophenolate mofetil (MMF)." | ( Atsumi, T; Hara, R; Hiromura, K; Kawaguchi, Y; Kikuchi, M; Kizawa, T; Miyazawa, H; Momoi, T; Mori, M; Nishimura, K; Nozawa, T; Sada, KE; Sakurai, N; Shimamura, S; Takasaki, Y; Takei, S; Tamura, N; Yasuda, S, 2015) |
| "CD4(+) T cells from Systemic Lupus Erythematosus (SLE) patients and healthy donors were treated by NaCl with or without SGK1 inhibitor." | ( Chen, W; Feng, X; Sun, L; Tang, X; Yang, X; Yao, G, 2015) |
| "The treatment of systemic lupus erythematosus (SLE) is complex, with a wide range of drugs commonly prescribed." | ( Chang, DJ; Kan, H; Molta, C; Nagar, S; Patel, J; Wallace, DJ, 2016) |
| "At baseline, demographics, systemic lupus erythematosus disease activity, serum creatinine concentration, estimated glomerular filtration rate and urine protein/creatinine ratio were similar among the treatment arms (with the exception of disease duration)." | ( Anderson, PW; Dooley, MA; Forrester, TD; Ginzler, EM; Radhakrishnan, J; Rovin, BH, 2016) |
| "Male and female patients with systemic lupus erythematosus, Wegener's granulomatosis/granulomatosis with polyangiitis, or other vaculitides, receiving CTX treatment." | ( Nahata, L; Quinn, GP; Sivaraman, V, 2016) |
| "We report three cases of systemic lupus erythematosus, wherein intravenous pulse methylprednisolone was administered." | ( Kanda, H; Kawahata, K; Ohshima, M; Yamamoto, K, 2019) |
| "A 38-year-old woman was diagnosed with systemic lupus erythematosus and received immunosuppressive therapy." | ( Hayashi, N; Imanishi, T; Kasagi, S; Kurimoto, C; Morinobu, A; Saegusa, J; Yamamoto, T, 2018) |
| "We included 124 patients with systemic lupus erythematosus or rheumatoid arthritis who were treated with HCQ." | ( Ahn, SJ; Joung, JY; Lee, BR; Ryu, SJ, 2017) |
| "With a diagnosis of systemic lupus erythematosus (SLE), systemic corticosteroid therapy was given, which led to the resolution of symptoms and laboratory abnormalities." | ( Akahori, D; Fukada, A; Funai, K; Suda, T; Toyoshima, M; Tsuchiya, K, 2018) |
| "He was diagnosed with systemic lupus erythematosus at 34 years of age and was being treated with oral tacrolimus (3 mg/day) and predonine (10 mg/day) for the past 15 months." | ( Hamada, Y; Horiki, N; Inoue, H; Katsurahara, M; Miura, H; Nakamura, M; Okuse, H; Sakuno, T; Shiono, Y; Takei, Y; Takeuchi, T; Tanaka, K; Yamada, R, 2018) |
| "Methods Mepacrine was added to 46 systemic lupus erythematosus patients unresponsive to treatment with the following drug combinations: hydroxychloroquine + prednisone + immunosuppressive drugs ( n = 24), hydroxychloroquine + prednisone ( n = 16), hydroxychloroquine + prednisone + retinoids ( n = 2), hydroxychloroquine alone ( n = 1), hydroxychloroquine + one immunosuppressive drug ( n = 1), hydroxychloroquine + prednisone + one immunosuppressive drug + belimumab ( n = 1) or hydroxychloroquine + prednisone + belimumab ( n = 1)." | ( Agesta, N; Martinez-Zapico, A; Ortego-Centeno, N; Porta, S; Ríos, R; Ruiz-Irastorza, G; Ugarte, A, 2018) |
| "One objective in the treatment of systemic lupus erythematosus (SLE) disease activity is to reduce long-term rates of organ damage." | ( Magder, LS; Petri, M, 2018) |
| "We analyzed four cases of systemic lupus erythematosus (SLE) with chylous pleural effusion treated in our hospital from June 2013 to May 2017." | ( Shang, C; Song, P; Zhang, J; Zhang, L, 2019) |
| "Venetoclax treatment in women with systemic lupus erythematosus was associated with exposure-dependent reductions in B lymphocytes, and to a lesser extent, total lymphocyte counts." | ( Minocha, M; Nader, A; Othman, AA, 2020) |
| "We report a 68-year-old man with systemic lupus erythematosus under treatment with immunosuppressants who developed non-HIV PML with brain lesions limited to the cerebellum and brainstem and successfully treated with a combination of mefloquine and mirtazapine." | ( Arai, S; Fujita, H; Hamaguchi, M; Hirata, K; Kikuchi, S; Matsuda, H; Nakamichi, K; Nakamura, T; Saijo, M; Shishido-Hara, Y; Suzuki, K; Uzuka, T, 2020) |
| "He was previously diagnosed with systemic lupus erythematosus (SLE) and antiphospholipid antibody syndrome (APS), and he had been treated with hydroxychloroquine and low-dose aspirin." | ( Akdogan, N; Bolek, EC; Demircan, C; Gokoz, O; Karaduman, A, 2020) |
| "Up to 80% of juvenile-onset systemic lupus erythematosus (jSLE) patients develop lupus nephritis (LN) that affects treatment and prognosis." | ( Beresford, MW; Bruce, I; Davies, JC; Donohue, SJ; Hedrich, CM; Midgley, A; Wright, RD, 2020) |
| "To compare the performance of the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and the SLEDAI-2K Glucocorticoids (SLEDAI-2KG) indices in identifying responders to standard of care therapy." | ( Anderson, N; Gladman, DD; Su, J; Touma, Z; Urowitz, MB; Zandy, M, 2021) |
| "These included systemic lupus erythematosus disease activity index (SLEDAI) score, serum albumin (Alb), 24‑h urinary protein, serum creatinine, anti‑ds‑DNAIgM, complement component 3 (C3), and the number of effective treatments and complications." | ( Bi, C; Li, Y; Qiu, X; Tian, B; Xu, T; Yao, L, 2020) |
| "A 52-year-old woman with new-onset systemic lupus erythematosus (SLE) was treated with low-dose cyclophosphamide (8 mg/kg, CY), but showed sudden headaches, disorientation and weakness." | ( Chen, J; Jin, Y; Li, C; Li, Z, 2020) |
| "We present a 49 year old woman with systemic lupus erythematosus and neuromyelitis optica spectrum disorder who was treated with mycophenolate mofetil, prednisone and recent plasmapheresis." | ( Chaudhry, ZA; Ginzler, E; Sharif, S; Terebelo, S, 2021) |
| "Women with systemic lupus erythematosus (SLE) are at risk of premature ovarian failure when treated with cyclophosphamide." | ( Chakravarty, EF; Chambers, A; Koelsch, KA; Scofield, RH; Talsania, M; Tsaliki, M, 2021) |
| "A 72-year-old woman with systemic lupus erythematosus treated for 24 years by HCQ received a kidney allograft." | ( Bories, MC; Bruneval, P; Gibault, L; Tharaux, PL, 2021) |
| "In patients with systemic lupus erythematosus, hydroxychloroquine treatment did not significantly increase the risk of cardiac arrhythmia or life-threatening ventricular arrhythmia regardless of the different hydroxychloroquine treatment duration, drug adherence rate, or daily dose." | ( Chan, KC; Li, LC; Lo, CH; Lo, TH; Su, CH; Tsai, CF; Wang, YH; Wei, JC, 2021) |
| "She was diagnosed with multisystem systemic lupus erythematosus and was initially treated with systemic steroids." | ( Ismail, R; Kariyawasam, D; Man, Y; Saqib, A, 2021) |
| "The patient was diagnosed to have systemic lupus erythematosus and immune-mediated intravascular haemolysis and was treated with prednisolone and hydroxychloroquine." | ( Bammigatti, C; Jose, A; Kolar Vishwanath, V; Magendiran, B, 2021) |
| "Baseline urine MCP-1 and EGF levels in systemic lupus erythematosus (SLE) patients and controls (total n = 101) were compared, and levels were correlated with clinicopathological findings and subsequent response to treatment." | ( Assanatham, M; Kantachuvesiri, S; Khiewngam, K; Kitiyakara, C; Ngamjanyaporn, P; Nongnuch, A; Pisitkun, P; Sathirapongsasuti, N; Worawichawong, S, 2022) |
| "It seems that in patients with systemic lupus erythematosus, vitamin D should be administered taking into account the phase of the disease." | ( Chegni, H; Heidarvand, M, 2022) |
| "In patients with systemic lupus erythematosus (SLE), lengthy treatment and long-term steroid use are the main risk factors for developing aortic aneurysms or aortic dissections." | ( Amano, A; Asai, T; Endo, D; Matsushita, S; Shimada, A; Yamamoto, T, 2022) |
| "In the anifrolumab systemic lupus erythematosus (SLE) trial programme, there was one trial (TULIP-1) in which BILAG-based Composite Lupus Assessment (BICLA) responses favoured anifrolumab over placebo, but the SLE Responder Index (SRI(4)) treatment difference was not significant." | ( Albulescu, M; Bruce, IN; Furie, RA; Hultquist, M; Kalunian, KC; Kleoudis, C; Maho, E; Manzi, S; Merrill, JT; Morand, EF; Puzio, P; Tanaka, Y; Tummala, R, 2022) |
| "As these pathways are dysregulated in systemic lupus erythematosus (SLE), we investigated the role of an itaconic acid derivative in the treatment of established murine lupus." | ( Blanco, LP; Carmona-Rivera, C; Claybaugh, D; Desta, E; Kaplan, MJ; Nakabo, S; Patino-Martinez, E; Pedersen, HL; Wang, X; Yu, ZX; Zhang, M, 2022) |
| "The prognosis in systemic lupus erythematosus (SLE) has improved due to better treatment and care, but cardiovascular disease (CVD) still remains an important clinical problem, since the risk of CVD in SLE is much higher than among controls." | ( Frostegård, J, 2023) |
| "Patients with systemic lupus erythematosus (SLE) associated with pulmonary arterial hypnertension (PAH) receive targeted therapy for PAH to decrease pulmonary arterial systolic pressure and significantly prolong their survival." | ( Ho, WJ; Lai, YJ; Yeh, YH; Yen, TH, 2022) |
| "All childhood-onset systemic lupus erythematosus patients treated with sirolimus in Children's Hospital of Hebei Province China were analyzed." | ( Cui, JY; Zhang, L, 2022) |
| "All childhood-onset systemic lupus erythematosus patients treated with sirolimus in Children's Hospital of Hebei Province China were analyzed." | ( Cui, JY; Zhang, L, 2022) |
| "All childhood-onset systemic lupus erythematosus patients treated with sirolimus in Children's Hospital of Hebei Province China were analyzed." | ( Cui, JY; Zhang, L, 2022) |
| "The pharmacological treatment of systemic lupus erythematosus (SLE) aims to decrease disease activity, progression, systemic compromise, and mortality." | ( Baracaldo-Santamaría, D; Poole, BD; Quaye, A; Rojas-Rodríguez, LC; Téllez Arévalo, AM; Tellez Freitas, CM, 2022) |
| "Four consecutive female systemic lupus erythematosus (SLE) patients with refractory skin lesions were treated with MLK (10 mg/d) in the Hospital Universitário Walter Cantídio of the Universidade Federal do Ceará." | ( da Silva, GFM; Martins, CDS; Nogueira, IA; Nunes, RM; Rocha, FAC, 2023) |
| "Patients with systemic lupus erythematosus (SLE) complicated with cryptococcal meningitis (CM) are easy to be misdiagnosed as neuropsychiatric lupus or tuberculous meningitis due to the lack of specificity of clinical symptoms, which may delay treatment." | ( Du, L; Liu, J; Ma, H; Wang, X; Wang, Y, 2023) |
| "Drug therapy for patients with systemic lupus erythematosus (SLE) aims to decrease symptom severity." | ( El Hussein, MT; Wong, C, 2023) |
| "Patients with systemic lupus erythematosus (SLE) are at increased risk of tuberculosis (TB) infection due to immune dysfunction and immunosuppressive therapy." | ( Bilukha, A; Komorovsky, R; Koshak, B; Slaba, U; Smiyan, S, 2023) |
| "Childhood-onset systemic lupus erythematosus (cSLE) is an autoimmune disease that results in significant damage and often needs more aggressive treatment." | ( Guo, L; Liu, C; Liu, J; Pan, L; Punaro, M; Yang, S, 2023) |